San Diego-dependent Viking Therapeutics marked itself as a serious competitor from the weight loss drug market place in February immediately after revealing promising data from a mid-phase trial of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when specified like a weekly injection and in March the